CA-DEGREED
23.6.2022 21:15:12 CEST | Business Wire | Press release
Degreed , the global innovator in professional lifelong learning chosen by more than one in three Fortune 50 companies, today announced the acquisition of talent academy platform, Learn In , and the return of Co-founder David Blake as CEO. Blake was previously the Co-founder and CEO of Learn In.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005917/en/
Learn In helps companies establish internal talent academies that bring together all the resources needed for building a highly skilled workforce, including the longer journey of developing deep skills. Learn In’s core features supplement those of the category-defining Degreed LXP (Learning Experience Platform), including a prepaid learning stipend card, a world-class skills marketplace and custom program builder, a tuition benefits manager, and dedicated coaching.
“A corporate capability academy goes beyond ‘a library of content,’” said global industry analyst and CEO of the Josh Bersin Company, Josh Bersin . “It’s a place people go to advance their job-related capabilities. It goes beyond technical and functional skills and focuses on the real business capabilities a company needs to thrive.”
Degreed plus Learn In will unify the broader range of development options people use, spanning daily learning to long-term upskilling for individual career growth and innovation within organizations.
Blake’s plans for the future of Degreed were divergent with the current direction, so an amicable decision was made that he return to the company as CEO and execute that vision.
Degreed thanks Dan Levin for the progress he has driven and his stewardship of the Degreed mission over the past 15 months, and is grateful for his accomplishments, including increasing our client base, establishing operational rigor for scale, and significantly expanding our partner ecosystem and overall global footprint.
“Businesses that can quickly build effective talent are the ones that will be able to deliver on strategic business goals,” said David Blake, Co-founder and CEO of Degreed . “Just as Degreed created the LXP market, Learn In has begun for talent academies. Now together, we have the product and technology to help our customers deliver business capabilities at scale with continued innovation in the learning and skills space.”
“At BMO, our strategy is to build a digitally-enabled bank that’s ready for the future. This means we need to equip employees with the skills they need for their job, their career, for the future of work, and as they follow their personal passions,” says Gina Jeneroux, Chief Learning Officer at BMO Financial Group . “As Degreed and Learn In come together, it will offer a more integrated opportunity for organizations like ours to engage employees and build a broader range of skills—from curious, ‘in-the-moment’ learning through to deeper reskilling and credentials.”
This is the fourth acquisition for Degreed, and Blake re-joins a seasoned Degreed leadership team from Bank of America, Mastercard, Danone, LinkedIn, Adobe, SAP and Saba.
About Degreed
Degreed empowers innovation through learning. As a changemaker on a global scale, we work with one in three Fortune 50 companies to spark a culture of learning across their enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need – through individual, collaborative and experiential modes of learning – to drive individual and business results. Founded in 2012, Degreed is headquartered in Pleasanton, California, with users spanning 191 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
About Learn In
Learn In helps companies establish talent academies that steer all the resources needed for building a highly skilled workforce. HR, Talent and L&D leaders use Learn In to modernize access to learning budgets and world-class programs, and to simplify the delivery of custom programs to employee groups. Learn In’s core features include a tuition benefits manager, a prepaid learning stipend card, a world-class program marketplace and custom program builder, and dedicated coaching. Now every employee can build deeper skills precisely aligned to company needs. Co-founded by the founders of Degreed, Learn In is backed by leading edtech & future-of-work investors, including Firework Ventures, Kickstart Fund, Album, GSV, and Village Global, and has been covered in CNBC, USA Today, EdTechReview, EdSurge, Fast Company, and Techcrunch.
Learn more about Learn In: Website | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005917/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom